Reproduced by "The Pink Sheet" from initial labeling for Maxzide and most recent PDR labeling version for Dyazide. MAXZIDE DOSAGE AND ADMINISTRATION -- The recommended dosage of MAZXIDE is one tablet daily with appropriate monitoring of serum potassium levels (see WARNINGS). Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE directly. In patients requiring 50 mg of hydrochlorothiazide in whom hypokalemia cannot be risked, therapy may be initiated with MAXZIDE. There is no clinical experience with doses exceeding one tablet daily. Clinical studies have shown that patients already taking less bioavailable formulations of triamterene and hydrochlorothiazide (totaling 50-100 mg of hydrochlorothiazide and 100-200 mg of triamterene) may be safely changed to one MAXZIDE tablet per day.; these patients should be monitored clinically and with serum potassium after the transfer. DYAZIDE DOSAGE AND ADMINISTRATION -- As determined by individual titration. Adults: The usual dose is one or two capsules twice daily after meals. Some patients may be maintained on one capsule daily or every other day. Maximum daily dose should not exceed four capsules, and at this dosage, the incidence of side effects may increase. Since 'Dyazide' has an antihypertensive effect, hypotensive drugs used concomitantly should be added at reduced dosage -- at least one half the usual dosage -- particularly if it is a ganglionic or peripheral adrenergic blocking agent. Adjust dosage as indicated. Children: Adequate information on the use of 'Dyazide' in children is not available. Note: Potassium supplementation used concurrently with other diuretics should be discontinued when titrating with Dyrenium (triamterene, SK&F Co.). They should not be reinstituted when the patient is placed on 'Dyazide' unless the triamterene component does not completely compensate for the potassium loss.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
